The mechanism and signaling alterations defined here, while irrelevant for IDH-mutant gliomas that tend to have low EMP3 levels [29, 66], are likely to be broadly applicable to other non-glioma tumor entities, as their RTK signaling outputs have also been shown to be supported by EMP3 [13, 23, 63]. The gene discussed is EMP3; the disease is glioma.